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Vacuolar protein sorting-35 (VPS35) is a retromer
component for endosomal trafficking. Mutations of
VPS35 have been linked to familial Parkinson’s dis-
ease (PD). Here, we show that specific deletion of
the VPS35 gene in dopamine (DA) neurons resulted
in PD-like deficits, including loss of DA neurons
and accumulation of a-synuclein. Intriguingly, mito-
chondria became fragmented and dysfunctional in
VPS35-deficient DA neurons, phenotypes that could
be restored by expressing VPS35 wild-type, but not
PD-linked mutant. Concomitantly, VPS35 deficiency
or mutation increased mitochondrial E3 ubiquitin
ligase 1 (MUL1) and, thus, led to mitofusin 2 (MFN2)
degradation and mitochondrial fragmentation. Sup-
pression of MUL1 expression ameliorated MFN2
reduction and DA neuron loss but not a-synuclein
accumulation. These results provide a cellular mech-
anism for VPS35 dysfunction inmitochondrial impair-
ment and PD pathogenesis.INTRODUCTION
Vacuolar protein sorting 35 (VPS35, also called Park17) is a key
component of the cargo-selective retromer complex that con-
sists of VPS35, VPS29, and VPS26. This retromer complex sorts
cargos into tubules for retrieval to the Golgi apparatus or to the
cell surface (Seaman, 2012). Prominent retromer cargos include
the following: the cation-independent mannose 6-phosphate re-
ceptor (CI-MPR) (Seaman, 2004), the iron transporter DMT1-II
(Tabuchi et al., 2010), the Wnt transport protein Wntless (Eaton,
2008), and the sortilin-related receptor SorLA (Nielsen et al.,
2007). Dysfunction of VPS35/retromer is a risk factor for both
Alzheimer’s disease (AD) and Parkinson’s disease (PD) patho-
genesis (Muhammad et al., 2008; Small et al., 2005; Small and
Petsko, 2015). VPS35 is reduced in the hippocampus (HIP) ofCell Relate-onset AD patients (Small et al., 2005). VPps35 haploinsuffi-
ciency enhances AD-like neuropathology in the Tg2576 mouse
model of AD (Wen et al., 2011). Suppressing VPS35 expression
in neonatal hippocampal neurons results in degenerative-like
morphology, including abnormal dendritic spines and swollen
axons (Wang et al., 2012). Intriguingly, VPS35 mutations have
been identified in autosomal-dominant PD patients (Vilarin˜o-
Gu¨ell et al., 2011; Zimprich et al., 2011), and VPS35 also is
reduced in the substantia nigra of PD patients (MacLeod et al.,
2013). However, it remains unclear whether and howVPS35 defi-
ciency or mutation contributes to PD pathogenesis.
Dysfunctional mitochondrial fusion/fission dynamics are
believed to be a culprit for neurodegenerative disorders, in-
cluding AD and PD (Knott et al., 2008). Interestingly, several
genes identified in PD patients encode proteins important for
mitochondrial fusion/fission dynamics, including mutations in
a-synuclein (also called Park1) and leucine-rich repeat kinase
2 (Lrrk2) (Park8) that cause autosomal-dominant PD and
mutations in parkin (Park2), DJ-1 (Park7), Pink1 (Park6), and
ATP13A2, which have been linked to autosomal-recessive PD
(Gasser, 2007; Lee et al., 2012a; Martin et al., 2011; Savitt
et al., 2006; von Coelln et al., 2006). Whereas these studies
have pointed to the impaired mitochondrial fusion/fission dy-
namics as a pathophysiological mechanism for both familial
and sporadic PD, the underlying molecular mechanisms of mito-
chondrial fusion/fission and the relationship between dysfunc-
tional mitochondrial fusion/fission and PD pathogenesis remain
to be further explored.
The fusion/fissiondynamicsofmitochondria arecritical not only
for controlling mitochondrial shape, size, and number, but also
for regulating mitochondrial functions (such as respiration and
cell death/survival), clearance (e.g., mitophage), and distribution.
Fission facilitates the distribution of mitochondria in response to
local demand for ATP, whereas fusion helps to replace damaged
mtDNA (Chan, 2006b; Karbowski and Youle, 2003). The fusion/
fission dynamics are controlled by opposing actions of different
dynamin-family members, such as dynamin-related protein 1
(Drp1) and mitofusins (Mfns) (Chan, 2006a; Itoh et al., 2013; Oka-
moto and Shaw, 2005). Fission requires Drp1 and its targeting toports 12, 1631–1643, September 8, 2015 ª2015 The Authors 1631
mitochondria via outer membrane binding partners, including
mitochondrial fission factor (Mff) (Loso´n et al., 2013). The activity
of Drp1 is regulated by post-translational modifications, including
phosphorylation, SUMOylation, and ubiquitination (Westermann,
2010). On the other hand, fusion requires mitochondrial outer
membrane proteins Mfns, including Mfn1 and MFN2. Both Mfns
are subjected to ubiquitination and proteasomal degradation,
and MFN2 is highly expressed in the brain and implicated in
Charcot-Marie-Tooth type 2A, an axonal degenerative disorder
(Zu¨chner et al., 2004).
In this paper, we provide evidence linking VPS35 deficiency
and mutation to mitochondrial impairments and dopaminergic
neuronal loss. VPS35 deficiency or mutation impairs mitochon-
drial fusion and function in cultured dopamine (DA) neurons, neu-
roblastoma cell lines (SH-SY5Y and NLT), and in the ventral
midbrain (VM). Additionally, we show that VPS35 regulates
mitochondrial fusion by promoting mitochondrial E3 ubiquitin
ligase 1 (MUL1) degradation and increasing MFN2 protein stabil-
ity. Suppression ofMUL1 expression in VPS35-deficient DA neu-
rons in culture and in the VM restored the PD-relevant deficits,
including MFN2 decrease, mitochondrial fragmentation, and
dopaminergic neuronal loss but not the increase of a-synuclein.
Taken together, our results suggest that VPS35 is a critical
regulator for MUL1 trafficking and degradation, thus increasing
MFN2 and promoting MFN2-mediated mitochondrial fusion
and DA neuron survival. Dysregulation of VPS35/retromer (due
to deficiency or VPS35 mutation) impairs MUL1 degradation
and mitochondrial fusion, which may underlie PD pathogenesis.
RESULTS
PD-Relevant Pathology in VPS35+/ Mice and in Mice
with Specific Depletion of VPS35 in DA Neurons
Null-allele VPS35 mutant mice (VPS35/) die early during em-
bryonic development (Wen et al., 2011). To address whether
VPS35 deficiency contributes to PD pathogenesis, we used
two other mouse models, VPS35 heterozygotes (VPS35+/)
and a newly generated mouse model with specific deletion of
VPS35 gene in DA neurons (VPS35DAT-Cre). The VPS35+/ mice
survived to adult age without a defect in lifespan (Wen et al.,
2011). Before the age of 6 months old, the PD-relevant deficits,
such as the loss of DA neurons and increase of a-synuclein,
were not obviously detected in VPS35+/ mice (Tang et al.,
2015). However, at 12 months old, 20% of DA neuron loss
was detected in the SNpc of VPS35+/ brain compared with
that of VPS35+/+ controls, and VPS35+/ mice showed an in-
crease in a-synuclein levels in the VM, too (Tang et al., 2015).
These results demonstrate that VPS35+/ mice display an age-
dependent DA neuron loss and accumulation of a-synuclein,
both pathological features of PD, suggesting that VPS35 hap-
loinsufficiency promotes PD pathogenesis.
VPS35 is expressed inmultiple cell types in the brain, including
DA neurons (MacLeod et al., 2013) and glial cells (data not
shown). To address if VPS35 expression in DA neurons is
essential for the prevention of PD-like deficits, we generated
VPS35DAT-Cre mice by crossing floxed VPS35 (VPS35f/f) with
DAT-Cremice (Figures S1A–S1C), where Cre recombinase is un-
der the control of the promoter of DA transporter gene (DAT) and1632 Cell Reports 12, 1631–1643, September 8, 2015 ª2015 The Auspecifically expressed in DA neurons (Figure S1C; Zhuang et al.,
2005). Thus, the VPS35 protein was specifically depleted in
SNpc-DA neurons (Figure S1D). The VPS35DAT-Cre mice survived
to adult age (up to 6months of age examined) with a slight reduc-
tion in body weight and size (Figure S1E). Remarkably, at young
adult age (2–3months old), VPS35DAT-Cre mice showed amarked
reduction in TH+ DA neurons at the SNpc and a decrease in TH+
fibers in striatum (STR), compared with those of littermate con-
trols (VPS35f/f) (Figures 1A–1D). The neuronal loss in SNpc of
VPS35DAT-Cre mice was confirmed by NeuN staining analysis
(Figures 1A and 1B). The reduction of TH proteins was further
verified by western blot analysis (Figures 1E and 1F). In addition,
increased a-synuclein levels were detected in the VM/SNpc-DA
neurons of VPS35DAT-Cre mice (Figures 1E–1H). Furthermore,
we examined if VPS35DAT-Cre mice showed PD-relevant motor
deficit. In the automatic gait test, VPS35DAT-Cre mice displayed
significant unsteady and weaker gaits (Figure 1I). VPS35DAT-Cre
mice also exhibited a decline in hindlimb stepping (rearing
behavior) in the cylinder observational test (Figure 1J), and
they took more time to descend the pole by the vertical pole
test (Figure 1K). In the open-field test, VPS35DAT-Cre mice
showed a significant reduction in the overall locomotor activity,
including shorter total distance traveled and increased immobile
time (Figure 1L). These results indicate that VPS35DAT-Cre mice
exhibit reduced locomotor activity.
Taken together, these results demonstrate that VPS35DAT-Cre
mice exhibit earlier onset of PD-relevant pathological features
than that of VPS35+/ mice, revealing the necessity of VPS35
expression in DA neurons for the prevention of PD pathogenesis.
Reduced Mitochondrial MFN2 in VPS35-Deficient DA
Neurons
To understand how VPS35 in DA neurons prevents PD patho-
genesis, we examined whether VPS35 deficiency altered levels
of proteins critical for endosomes (EEA1), Golgi (GM130), lyso-
somes (LAMP1), mitochondrial fission/fusion (Drp1 and MFN2),
mitochondria (Tom20), and proteins implicated in PD pathogen-
esis, such as Lrrk2, Pink1, and Parkin. Homogenates prepared
from various brain regions, including VM, HIP, and STR, of
control (VPS35f/f) and VPS35DAT-Cre mice were subjected to
western blotting analyses. As shown in Figures 2A and 2B, no
obvious change was observed for EEA1, GM130, LAMP1,
Lrrk2, Pink1, Parkin, Tom20, and Drp1. However, MFN2 was
significantly reduced in the VM, but not the HIP or STR regions,
of VPS35DAT-Cre mice (Figures 2A and 2B). MFN2 is a GTPase
embedded in the outer membrane of the mitochondria (Chen
et al., 2003).
We thus examined if mitochondrial MFN2 is reduced in
VPS35-deficient brain. Mitochondrial fractions were purified
from the VM region of control and VPS35+/ mice at different
ages and subjected to western blotting. MFN2 was reduced in
VPS35+/ VM mitochondria, whereas no obvious change was
observed for Lrrk2, Pink1, Parkin, ATP5a, Tom20, and Drp1,
even in aged mutant mice (Figures 2C and 2D). We next exam-
ined if mitochondrial MFN2 is reduced in VPS35-deficient
neurons in culture. Indeed, a marked MFN2 reduction in Mito-
RFP-labeled mitochondria was detected in neurons expressing
microRNA (miRNA)-VPS35, which reduced VPS35 by >80%thors
Figure 1. PD-Relevant Neuropathology in VPS35DAT-Cre Mice
(A and B) Loss of TH+-DA neurons in 2- to 3-month-old VPS35DAT-Cre SNpc. (A) Representative images of midbrain coronal sections of VPS35DAT-Cre and f/f
littermates are shown (scale bars represent 200 mm). (B) Datawere quantified by stereological analysis total numbers of TH+ or NeuN+ cells in SNpc and are shown
as mean ± SEM (n = 4; *p < 0.05).
(C and D) Immunostaining analysis showing reduced TH+ neuronal processes in 2- to 3-month-old VPS35DAT-Cre STR. (C) Representative images of the whole
STR are shown (scale bars represent 400 mm). (Inset) Close-up views of neuronal processes are shown (scale bars represent 10 mm). (D) Quantification of TH
optical density is shown (mean ± SEM; n = 4; *p < 0.05).
(E and F) Western blot analysis of TH and a-synuclein (a-syn) levels from ventral midbrain (VM) of 2- to 3-month-old VPS35DAT-Cre and VPS35f/f mice. Data were
quantified and are presented in (F) as mean ± SEM (n = 4; *p < 0.05).
(G and H) Accumulation of a-syn in VPS35DAT-Cre SNpc-DA neurons. Midbrain coronal sections of indicated mice were immunostained with a-syn (red) and
TH (green) antibodies. (G) Representative images are shown (scale bar represents 10 mm). (H) Quantitative data of a-syn somatic accumulation in TH+ neurons
(%, over total TH+ neurons) in SNpc are presented (mean ± SEM; n = 4; *p < 0.01).
(I–L) Behavioral tests on VPS35DAT-Cre mice and control littermates. (I) Grip strength: forelimb grip strength was determined by a digital weight gauge. (J) Cylinder
observational test: rearing frequency was recorded. (K) Pole test: each mouse was placed head upward on a round vertical pole and performance was deter-
mined by the latency(s) of the mouse to turn downward and completely descend the pole. (L) Open-field tests: total distance traveled and immobile time in open-
field test were quantified in (E). Data are presented as mean ± SEM (n = 4–6; *p < 0.05).(Wang et al., 2012; Figures 2E and 2F). MFN2 reduction also
was confirmed by western blot analysis of lysates of cultured
DA neurons from VPS35DAT-Cre mice (Figures 2G and 2H). A
similar MFN2 reduction was detected in small hairpin RNA
(shRNA)-VPS35-expressing SH-SY5Y and NLT cells by both
western blot and immunostaining analyses (Figure S2). Taken
together, these results suggest that VPS35 deficiency in DA neu-
rons as well as neuronal cell lines reduced mitochondrial MFN2,
identifying a potential molecular target.Cell ReMitochondrial Fragmentation in VPS35DAT-Cre DA
Neurons and Neurons Expressing PD-Linked VPS35
Mutant
MFN2 is essential for mitochondrial fusion (Chen et al., 2003),
which is frequently altered by PD-linked genetic mutations (Hael-
termanet al., 2014).We thusexaminedmitochondrialmorphology
in VPS35-deficient DA neurons. Overall, VPS35DAT-Cre DA neu-
rons (TH+) in culture showed no obvious defect in neuronal pro-
cesses (revealed by TH and Tuj1 staining) (Figure 3A; data notports 12, 1631–1643, September 8, 2015 ª2015 The Authors 1633
Figure 2. Reduced Mitochondrial MFN2 in Vps35-Deficient DA Neurons
(A and B) Reduced MFN2 in Vps35DAT-Cre VM, but not hippocampus (HIP) or striatum (STR). Soluble extracts from HIP, VM, and STR of indicated mice were
subjected to western bot analysis (A, representative blots; B, quantification of protein levels comparedwith Vps35f/f controls). Data are presented asmean ±SEM
(n = 3 mice/genotype; *p < 0.05).
(C andD) Reducedmitochondrial MFN2 in aged Vps35+/ VM.Mitochondrial fractions of indicatedmicewere subjected to western bot analysis (C, representative
blots; D, quantification of protein levels compared with Vps35+/+ controls). Data are presented as mean ± SEM (n = 3 mice/genotype; *p < 0.05).
(E and F) Reducedmitochondrial MFN2 in miRNA-Vps35-expressing neurons. (E) Representative images of transfected neurons are shown. (F) Quantitative data
(normalized by control miR) are shown (mean ± SEM; n = 5 neurons; *p < 0.05).
(G and H) Reduced MFN2 levels in Vps35DAT-Cre primary DA neurons. (G) Representative blots are shown. (H) Quantification of protein levels (normalized with
Vps35f/f controls) is shown. Data are presented as mean ± SEM (n = 3 mice/genotype; *p < 0.05).shown). However, mitochondria of VPS35-depleted DA neurons
(revealed by Tom20, a marker for mitochondrial outer membrane)
were shorter and rounder than those in control neurons (Figures
3A and3B), suggestingmitochondrial fragmentation. Importantly,
the mitochondrial fragmentation in VPS35-depleted neurons was
mitigated by expressing GFP-fused VPS35-wild-type (WT), but
not VPS35-D620N, the PD-linked VPS35 mutant (Figures 3C
and 3D). These results thus reveal a cell-autonomous function of
VPS35 in preventing mitochondrial fragmentation in neurons,
and they provide a possible pathophysiological mechanism of
the PD-linked VPS35-D620N mutation.
Note that mitochondrial fragmentation also was observed in
NLT and SH-SY5Y neuronal cell lines that were transfected with
miRNA-VPS35 (Figures S3A–S3D) or shRNA-VPS35 (Figures
S3E–S3G). This mitochondrial fragmentation was restored by
expressing shRNA-resistant, but not shRNA-sensitive, VPS35 in1634 Cell Reports 12, 1631–1643, September 8, 2015 ª2015 The AushRNA-VPS35-expressing NLT cells (Figures S3E–S3G). These
results demonstrate that VPS35 deficiency or mutation results in
mitochondrial fragmentation in DA neurons as well as neuronal
cell lines.
Impaired Mitochondrial Function in VPS35-Deficient DA
Neurons
Mitochondrial fusion morphology is believed to be critical for the
maintenance of mitochondrial respiratory capacity in mamma-
lian cells (Westermann, 2012). Deficits in mitochondrial res-
piration are critically associated with dopaminergic neuronal
dysfunction in PD (Itoh et al., 2013). We thus examined mito-
chondrial respiratory capacity in VPS35-deficient DA neurons
by use of the Seahorse platform to measure real-time oxygen
(O2) consumption rates (OCRs). The basal oxygen consumption
rate (BR) was slightly higher in DA neurons from VPS35DAT-Crethors
Figure 3. Mitochondrial Fragmentation in
VPS35DAT-Cre DA Neurons
(A and B) Increased mitochondrial fragmenta-
tion in primary DA/TH+ neurons (7 DIV) from
VPS35DAT-Cre midbrain, compared to VPS35f/f
controls. Midbrain neurons of E18.5 mice were
cultured for 7 days (7 DIV). Mitochondria were
labeled by Tom20 staining. (A) Representative
images and close-up views of mitochondria in
neurites are shown. (A’) Close-up views of mito-
chondria in neuron soma region are shown (scale
bars represent 10 mm). (B) Quantifications of
mitochondrial length and aspect ratio (mitochon-
drial major axis over minor axis) are shown. Shown
are grouped column scatter (left, with mean indi-
cated by the line) and as aspect ratio (right, pre-
sented asmean ±SEM; n = 400mitochondria from
20 different neurons of each group; *p < 0.05).
(C and D) Reduced mitochondrial fragmentation in
VPS35DAT-Cre DA neurons expressing VPS35-WT,
but not VPS35-D620N. Primary VPS35DAT-Cre DA
neurons were transfected with VPS35-WT-GFP or
VPS35-D620N-GFP (GFP was fused with the
VPS35-C terminus) at 6 DIV and analyzed for
mitochondrial morphology at 10 DIV. (C) Repre-
sentative images are shown (scale bars represent
10 mm). (D) Quantifications of mitochondrial length
and aspect ratio are shown. Data are presented as
mean ± SEM (n = 200 mitochondria from ten
different neurons; *p < 0.01).mice compared with controls, whereas no difference in oxygen
consumption was observed following treatment of neurons
with oligomycin (an inhibitor of ATP synthase), which serves as
a negative control (Figures 4A and 4B). However, the maximal
respiratory rates (MRs) induced by mitochondrial un-coupler
(carbonyl cyanide-p-trifluoromethoxyphenylhydrazone [FCCP])
treatment were markedly reduced in VPS35-depleted DA neu-
rons (Figures 4A and 4B), which resulted in a deficiency in spare
respiratory capacity (SR) (Figure 4C). A similar mitochondrial MR
deficit also was detected in VPS35+/ DA neurons (data not
shown). These results thus indicate dysfunctional mitochondria
in cultured VPS35-deficient DA neurons.
Mitochondrial membrane potential (Jm) is another indicator of
mitochondrial health and function (Chen, 1988). We then asked if
VPS35 deficiency alters mitochondrial membrane potential by
using the potentiometric fluorescent dye tetramethylrhodamine
methylester (TMRM), as its fluorescent intensity reflects theCell Reports 12, 1631–1643, Semitochondrial membrane potential. NLT,
a GnRH neuronblastoma cell line, was
used because VPS35 is highly expressed
in NLT cells (Wen et al., 2011) and the
spread cell morphology in NLT cells pro-
vides a technical advantage for this
assay. As shown in Figures 4D and 4E,
TMRM accumulated in control NLT cells
and the fluorescence was decreased by
treatment with carbonyl cyanide m-chlor-
ophenyl hydrazine (CCCP), a proton iono-
phore that depolarizes mitochondria,indicating the specificity of TMRM labeling. However, TMRM
signal was reduced in miRNA-VPS35-expressing cells, which
agrees with the increased respiratory rate in OCR test (Figures
4D–4F). Taken together, these results suggest that mitochondrial
dysfunction occurs in VPS35-deficient DA neurons as well as
NLT cells.
In Vivo Mitochondrial Deficit in VPS35-Deficient
Midbrain
To determine whether mitochondrial structures were altered in
VPS35-deficient brain, we carried out transmission electron
microscopy (TEM) analysis. As shown in Figures S4A–S4D,mito-
chondria were smaller in VPS35+/ SNpcs in 4-month-old mice.
The deficit was undetectable in STR of the mutant mice, but
became prominent in 12-month-old mutant mice (Figures S4B,
S4C, and S4E). The STR mitochondria in 12-month-old mutant
mice were condensed and damaged (Figure S4F). These resultsptember 8, 2015 ª2015 The Authors 1635
Figure 4. Impaired Mitochonchrial Function
in VPS35DAT-Cre DA Neurons and VPS35-
Deficient NLT Cells
(A and B) Real-time O2 consumption rate (OCR)
was measured in 7 DIV primary DA neurons by a
Seahorse XF96 analyzer. For validation of the
measurement, we used the ATP synthase inhibitor
oligomycin (2 mM) after recording basal line, fol-
lowed by treatments of the pharmaceutical un-
coupler FCCP (3 mM) and the complex I inhibitor
rotenone (1 mM). Representative traces of OCR are
indicated in (A), each time point representing the
mean ± SEM, and averaged OCR profiles from at
least four animals are shown in (B). *p < 0.05.
(C) The SR changes (compared with BR) are
shown with bar graph. Data are presented as
mean ± SEM (*p < 0.01).
(D–F) Decreased mitochondrial membrane po-
tential in miRNA-VPS35-expressing NLT cells. (D)
Representative TMRM time-lapse images of
transfected NLT cells, without or with 20 mM
CCCP, are shown (scale bar represents 10 mm). (E)
Quantitative data are shown. Arrow indicates
CCCP treatment. (F) DJm in NLT cells expressing
control or miR-VPS35 is shown (mean ± SEM; n =
50 cells; *p < 0.01).thus indicate that mitochondria appear to be fragmented and
abnormal in morphology in aged VPS35+/ midbrains and
STRs, which may underlie PD-relevant neuropathology.
To ascertain if mitochondria in VPS35+/ brain are dysfunc-
tional, we measured mtDNAs, which are largely dependent on
fusion and have been used as an indicator of mitochondrial func-
tion (Chan, 2006a). The ratio of mtDNAs over nuclear DNAs
(ncDNAs) in VM and STR was similar between VPS35+/+ and
VPS35+/mice at 3months of age (Figure S4G). However, the ra-
tio was markedly decreased in 12-month-old VPS35+/ VM and
STR, compared with that of WT controls (Figure S4G, bottom).
This effect was not observed in the HIP, indicating regional spec-
ificity. These results provide additional evidence for age-depen-
dent and brain region-specific mitochondrial dysfunction.
MFN2 Protein Reduction Associated with Increased
Ubiquitination
We then investigated the underlying molecular mechanisms for
MFN2 reduction in VPS35-deficient brain/neurons. The MFN2
reduction was not caused by a problem in transcription, because
a comparable level of MFN2 mRNA was detected between con-
trol andmutantmice (Figure S2E). MFN2 can be degraded by the
ubiquitin-proteasome system (UPS) (Tanaka et al., 2010). We
thus speculated that the MFN2 reduction might be due to
MFN2 degradation by the UPS. This notion was supported by
the observation that MG132, a proteasome inhibitor, restored
MFN2 levels in VPS35-deficient DA neurons (Figures S5A and
S5B) or SH-SY5Y cells (Figures S5C and S5D). Consistently,
MFN2 ubiquitination was increased in VPS35-deficient SH-
SY5Y cells or cells expressing VPS35 mutant (D620N) (Figures
S5E and S5F). Interestingly, expression of shRNA-resistant
VPS35-WT, but not VPS35-D620N, also restored MFN2 levels1636 Cell Reports 12, 1631–1643, September 8, 2015 ª2015 The Auin VPS35-deficient SH-SY5Y cells (Figures S5C and S5D). These
results suggest that VPS35 deficiency or mutation (D620N) re-
ducesMFN2 protein likely by UPS-mediatedMFN2 degradation.
Increase of Mitochondrial E3 Ubiquitin Ligase MUL1
A previous proteomic study suggested that MUL1 (also known
as MAPL for mitochondrial-anchored protein ligase) interacts
with VPS35/retromer (Braschi et al., 2010). Recently, MUL1, a
mitochondrial outer membrane protein, was found to be a critical
E3 ubiquitin ligase ofMFN2 (Lokireddy et al., 2012). To determine
if MUL1 was involved in VPS35 regulation of MFN2, we exam-
ined MUL1 protein levels in mitochondrial fractions of different
brain regions of control and mutant mice (at 4 months old).
MUL1 levels were selectively elevated in mitochondrial fractions
of VPS35+/ VMs and STRs, but not HIP, corroborating with
MFN2 reduction (Figures 5A and 5B). In VPS35-deficient SH-
SY5Y cells, a MUL1 increase was also detectable, which was
associated with a decrease in MFN2 (Figures 5C and 5D),
revealing a reciprocal relationship between MUL1 and MFN2
that suggests MFN2 as an MUL1 substrate. Additionally, the
MUL1 increase was mitigated by co-expressing shRNA-resis-
tant VPS35-WT but not VPS35-D620N (Figures 5C and 5D).
Finally, expression of this and other PD-associated mutants
(P316S or R524W) was sufficient to increase MUL1 and reduce
MFN2 (Figures 5E and 5F). These results suggest that VPS35
regulates MUL1 protein level, which may be involved in VPS35
deficiency-induced MFN2 reduction.
To understand how VPS35 regulates MUL1 protein level, we
measured the half-life of MUL1 in control and shRNA-VPS35-ex-
pressing SH-SY5Y cells. The half-life of MUL1 in control cells
was about 4 hr (Figures 6A and 6B). However, it dramatically
increased in shRNA-VPS35-expressing cells, with no detectablethors
Figure 5. Increased MUL1 in VPS35+/ Midbrains and in SH-SY5Y Cells Expressing shRNA-VPS35 or PD-Linked VPS35 Mutants
(A and B) Increased mitochondrial-MUL1 protein in 4-month-old VPS35+/ VM and STR, but not HIP. Mitochondrial fractions were subjected to western blotting
with the indicated antibodies. (A) Representative blots are shown. (B) Quantification of data (normalized by VPS35+/+ control) is shown.
(C and D) Association of increasedMUL1with decreasedMFN2 in shRNA-VPS35-expressing SH-SY5Y cells, which was restored by expressing shRNA-resistant
VPS35-WT, but not VPS35-D620N. (C) Representative blots are shown. (D) Quantification of MUL1 and MFN2 protein (normalized by Mock control) is shown.
(E and F) Association of increased MUL1 with decreased MFN2 in SH-SY5Y cells expressing PD-linked VPS35 mutants. (E) Representative blots are shown. (F)
Quantification ofMUL1 andMFN2protein levels (normalized by VPS35-WT control) is shown.Data in (B), (D), and (F) are presented asmean±SEM (n = 3; *p < 0.05).reduction within 8 hr of experiments (Figures 6A and 6B). These
results indicate that VPS35 is necessary for MUL1 degradation.
To determine if MUL1 distribution in mitochondria was altered in
VPS35-deficient cells, we stained for MUL1 in miRNA-VPS35-
expressing NLT cells and VPS35+/ neurons. As shown in Fig-
ures 6C–6E, exogenous MUL1 (GFP-MUL1) and endogenous
MUL1 in mitochondria were markedly increased in VPS35-defi-
cient NLT and neurons, compared to those in control cells. The
increase of mitochondrial-MUL1 in VPS35+/ neurons also was
ameliorated by expressing VPS35-WT, but not VPS35-D620N
(Figures 6F and 6G). These results were in agreement with
increased MUL1 in mitochondrial fractions of VPS35+/ VMs
(Figures 5A and 5B). These results led us to propose that
VPS35 promotes the degradation of MUL1 to reduce MUL1 level
in mitochondria, whichmay be critical for maintainingMFN2 pro-
tein level for mitochondrial fusion.
Requirement of MUL1 for MFN2 Reduction,
Mitochondrial Fragmentation, and DA Neuron Loss in
VPS35-Deficient Cells or Midbrain
To investigate whether MUL1 is involved in MFN2 reduction
in VPS35-deficient cells, we generated shRNA-MUL1 (shR-Cell ReMUL1), which specifically and efficiently suppressed MUL1
expression (Figures S6A–S6C). As shown in Figures S6A and
S6B, co-expressing shR-MUL1 prevented miRNA-VPS35 from
reducing MFN2 in SH-SY5Y cells. Moreover, shR-MUL1 pre-
vented VPS35 deficiency from causing mitochondrial fragmenta-
tion in either miRNA-VPS35-expressing NLT cells (Figures S6D
and S6E) or neurons (Figures S6F and S6G). These results
demonstrate that MFN2 reduction and mitochondrial fragmenta-
tion by VPS35 deficiency require MUL1, providing a molecular
mechanism by which VPS35 deficiency causes MFN2 degrada-
tion and mitochondrial fragmentation.
We further tested this view by determining whether MUL1
causes MFN2 reduction in VPS35-deficient DA neurons in vivo.
To this end, adenovirus (serotype 5)-encoding shRNA against
mouse MUL1 (AAV-shR-MUL1-GFP) was generated, which
was injected into VPS35+/+ and VPS35+/ SNpc (at 6 months
of age) (Figure 7A). Two months post-virus injection, GFP
expression throughout the injected SNpc was observed (Fig-
ure 7B) and >80% of TH-positive neurons expressed GFP (Fig-
ure 7B, insets). As DA neurons of the SNpc project to the STR
to create the nigral-striatal pathway, the GFP signal in the ipsi-
lateral, but not contralateral (CON), STR also was detected,ports 12, 1631–1643, September 8, 2015 ª2015 The Authors 1637
Figure 6. Impaired MUL1 Degradation and Increased MUL1 Distribution in Mitochondria in VPS35-Deficient Cells
(A and B) MUL1 protein degradation was inhibited by shRNA-VPS35. SH-SY5Y cells were transfected with control and shRNA-VPS35 (at 80% efficiency).
Transfected cells were incubated with CHX (100 mg/ml) for the indicated times. Cell lysates were subjected to western blotting using the indicated antibodies
(A, representative blots; B, quantification of MUL1 levels, each time point representing the mean ± SEM normalized with time 0).
(C–E) MUL1 distribution in mitochondria was increased in miRNA-VPS35-expressing NLT cells. GFP-MUL1 (C) and endogenous MUL1 (D) were increased in
mito-RFP-labeled mitochondria of miRNA-VPS35-expressing cells (C and D, representative images; scale bar represents 5 mm). MUL1 colocalization with
mitochondria (Mito-RFP) is presented in (E) as mean ± SEM; n = 3, each with 20 cells; *p < 0.05.
(F and G) MUL1 distribution in mitochondria was increased in VPS35+/ neurons, which was reduced by GFP-VPS35-WT, but not GFP-VPS35-D620N. (F)
Representative images are shown (scale bar represents 10 mm). (G) Quantification of MUL1 co-localization with mitochondria is shown (mean ± SEM; n = 3, each
with 20 cells; *p < 0.05).indicating the specificity of the injection (Figure 7B). Western blot
analysis confirmed that AAV-shR-MUL1-GFP infection efficiently
suppressed MUL1 expression in both WT and VPS35+/ VMs
(Figures 7C and 7D). Remarkably, the MFN2 level was restored
to normal in VPS35+/ VMs and increased in WT VMs by sup-
pressing MUL1 expression (Figures 7C and 7D), indicating the
necessity of MUL1 for the MFN2 reduction in vivo.
Interestingly, upon AAV-shR-MUL1-GFP injection, TH+ neuron
counts in VPS35+/ SNpc were restored to a nearly normal range
(Figures 7E and 7F). The TH+ neurons in the CON side of
VPS35+/ SNpc remained lower than that of VPS35+/+ controls
(Figures 7E and 7F), indicating the specificity. Consistently, TH1638 Cell Reports 12, 1631–1643, September 8, 2015 ª2015 The Auprotein was reduced in VPS35+/ VMs, which was restored by
infection with the virus of AAV-shR-MUL1-GFP (Figure 7C).
TH+ dopaminergic nerve terminals also were decreased in
VPS35+/ STR compared with those of WT controls, which
also were rescued by suppressing MUL1 expression (Figures
7G and 7H). We further measured DA neurotransmitter level by
high-performance liquid chromatography (HPLC) in VPS35+/+
and VPS35+/ STR injected with or without the shR-MUL1-
GFP virus. Whereas DA was markedly reduced in VPS35+/
STR (compared with that of WT controls), suppressing MUL1
expression prevented this DA reduction (Figure 7I). It is note-
worthy that the increase of a-synuclein in VPS35+/ VM wasthors
Figure 7. Restoration of MFN2 Reduction and DA Neuron Loss by Suppressing MUL1 Expression in VPS35+/ SNpc
(A) Schematic of AAV injection strategy. AAV5-shR-MUL1-GFPwas stereotactically injected into VPS35+/+ or Vps+/mice brains at 6months of age. Twomonths
post-injection, coronal brain sections, VMhomogenates, or STR homogenates were collected and subjected to immunohistochemical staining, western blot, and
HPLC analysis.
(B) AVV5 infect the DA neurons in coronal brain sections. Contralateral (CON) and ipsilateral (shR-MUL1) substantia nigra (SNpc) are indicated (scale bar rep-
resents 1mm). Right insets show magnified images of the marked squares (scale bar represents 50 mm).
(C) Representative western blots of homogenates of VM derived from the virus ipsilateral (shR-MUL1) and CON hemispheres.
(D) Quantification of data from (C). RelativeMUL1 andMFN2 protein levels were normalized by un-injection side of VPS35+/+. Means ±SEM (n = 3) are shown; *p <
0.05.
(E and F) Stereological analysis of TH-positive dopaminergic neurons in the SNpc. (E) Representative images show TH immunostaining analysis in the virus-
injected SNpc (scale bar represents 200 mm). Insets show magnified images (scale bar represents 10 mm) and arrows indicate axon swelling. Quantification
analysis of TH+ or NeurN+ cells in each hemisphere (mean ± SEM; n = 3) are presented in (F). *p < 0.05 by one-way ANOVA with post hoc analysis.
(G and H) Distribution of TH-immunoreactive fibers in the STR. (G) Representative images of TH staining analysis in adjacent sections of the injected STR (scale
bar represents 400 mm). Insets show magnified images (scale bar represents 10 mm). (H) Quantification of TH-immunoreactive intensity in the STR. Data are
expressed as the percentage of the TH intensity of VPS35+/+ CON side. Mean ± SEM; n = 3; *p < 0.05 by one-way ANOVA with post hoc analysis.
(I) Dopamine levels in the VPS35+/+ and VPS35+/ STR were measured by HPLC analysis. Isoproterenol was added as internal control (n = 3). Data are presented
as mean ± SEM; *p < 0.05 by one-way ANOVA with post hoc analysis.
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unchanged by suppression of MUL1 expression (Figure 7C).
Collectively, these findings suggest that VPS35 deficiency re-
duces MFN2 and promotes dopaminergic neuronal loss, which
can be alleviated by suppression of MUL1 expression.
Next, we determined whether MUL1 also causes MFN2 re-
duction in DA neurons expressing PD-linked VPS35 mutant
(D620N) in vivo. To this end, AAV5-encoding GFP-T2A-VPS35-
D620N was generated, which was injected or co-injected with
shR-MUL1 virus into WT-SNpc (at 3 months old) (Figure S7A).
Western blot and immunostaining analysis confirmed the
VPS35-D620N expression and the MUL1 suppression by infect-
ing WT VM with both viruses (Figures S7B–S7D). Indeed, MFN2
was reduced in VMs expressing VPS35-D620N, which was
restored to normal in VMs co-expressing shRNA-MUL1 (Figures
S7B and S7C). Accordantly, the TH+ neurons were lower in
VPS35-D620N-expressing SNpc, which was attenuated by co-
expression of shR-MUL1 (Figures S7G and S7H). Interestingly,
in VPS35-D620N-expressing DA neurons, mitochondria were
shorter and round (indicators of mitochondrial fragmentation)
compared with those of uninfected or AAV-GFP-infected con-
trol neurons (Figures S7E and S7F). Moreover, co-injection
with shR-MUL1 virus prevented mitochondrial fragmentation
in these VPS35-D620N-expressing DA neurons (Figures S7E
and S7F). Taken together, these results suggest that VPS35
mutation (D620N) acts as VPS35 deficiency, promoting dopami-
nergic neuronal loss likely by increasing MUL1-mediated MFN2
degradation.
DISCUSSION
This study has the following major findings. First, VPS35 expres-
sion in DA neurons is essential for prevention of PD-relevant def-
icits. Second, VPS35 expression in DA neurons is necessary for
mitochondrial fusion and function, an event critical for DA neuron
survival. Third, VPS35 regulates the trafficking and degradation
of the E3 ubiquitin ligase MUL1, thus suppressing MUL1-medi-
ated MFN2 degradation, and promotes mitochondrial fusion.
Fourth, elevated MUL1 in VPS35-deficient DA neurons contrib-
utes to MFN2 reduction, mitochondrial fragmentation, and DA
neuron loss, but not to the accumulation of a-synuclein. Our
work thus provides evidence for VPS35/retromer’s unrecog-
nized function in regulating mitochondrial fusion dynamics, and
it suggests a working model in which dysregulation of VPS35/
retromer’s function results in an increase of mitochondrial
MUL1 E3 ubiquitin ligase, a decrease in MFN2, and an impair-
ment of mitochondrial fusion and function, which may underlie
VPS35 deficiency/mutation-associated PD pathogenesis.
The dysfunction of VPS35/retromer is believed to be a risk fac-
tor for the pathogenesis of both AD and PD. Whereas VPS35
deficiency enhances AD neuropathology in the Tg2576 mouse
model of AD (Wen et al., 2011), it was unclear if VPS35 deficiency
contributes to PD pathogenesis. Here we provide evidence for
VPS35 deficiency or mutation to promote PD pathogenesis.
First, VPS35+/ mice exhibit age-dependent PD-like deficit,
including TH+ DA neuron loss and an accumulation of a-synu-
clein (Tang et al., 2015). Second, young adult VPS35DAT-Cre
mice, which specifically delete the VPS35 gene in DA neurons
(Figure S1), show an earlier onset PD-like deficit than VPS35+/1640 Cell Reports 12, 1631–1643, September 8, 2015 ª2015 The Aumice (Figure 1), revealing a genetic dose dependency and the
importance of VPS35 expression in DA neurons. Third, DA neu-
rons expressing VPS35-D620N (a PD-linked mutation, via AAV
virus) also exhibited a reduction in TH+ neurons (Figure S7).
How does VPS35 deficiency or mutation in DA neurons pro-
mote PD pathogenesis? The underlying mechanisms may be
complex, as VPS35/retromer regulates the function and traf-
ficking of numerous cargos (Small and Petsko, 2015). Here, we
propose that dysfunction in mitochondrial fusion dynamics
may be a critical mechanism underlying VPS35 deficiency- or
mutation-associated PD pathogenesis for the following reasons.
First, the MFN2 protein, a GTPase essential for mitochondrial
fusion, was decreased in both VPS35+/ and VPS35DAT-Cre VM
and in VPS35-deficient primary DA neurons (Figure 2), which
correlates well with the mitochondrial deficit. Second, expres-
sion of VPS35-WT, but not the PD-linked mutant D620N, in
VPS35-deficient cells was capable of restoring the phenotypes
(such as MFN2 reduction and mitochondrial fragmentation;
Figures 3 and 5). Third, DA neuron-selective MFN2 knockout
mice (MFN2/ or MFN2DAT-Cre) showed mitochondrial and
PD-relevant deficits (Lee et al., 2012b; Pham et al., 2012). Fourth,
MFN2 is mutated in human axonal degenerative disorder Char-
cot-Marie-Tooth type 2A (Zu¨chner et al., 2004), and MFN2
loss is implicated in the pathogenesis of not only Charcot-
Marie-Tooth type 2A but also PD. Finally, the dysregulation of
mitochondrial function has been linked to the pathogenesis of
multiple neurodegenerative disorders, and the evidence in PD
is particularly strong (Haelterman et al., 2014). Mutations in
several genes identified in PD patients encode proteins critical
for mitochondrial dynamics as well as quality control. Among
these genes, a-synuclein, Pink1, Parkin, and DJ-1, their func-
tions on mitochondrial dynamics have been investigated ex-
tensively. Although their functions in regulating mitochondrial
fusion or fission dynamics remain controversial, studies from
Drosophila, mouse, and human cell lines support the view for
the critical roles that these genes play in maintaining mitochon-
drial morphology, function, and mitophage-mediated clearance
of damaged mitochondria in PD (Lee et al., 2012a; Pickrell and
Youle, 2015).
VPS35 is a well-recognized key component of the retromer
essential for endosome-to-Golgi retrieval of transmembrane pro-
teins/cargos. This study suggests a crucial role for VPS35 in regu-
lating mitochondrial fusion dynamics, raising a question of how
VPS35/retromer, a critical endosomal pathway regulator, regu-
lates MFN2 protein degradation and mitochondrial protein traf-
ficking. Results in our cellular and in vivo mouse studies have
led to a working model, in which VPS35 promotes mitochondrial
fusion dynamics by increasing MUL1 E3 ubiquitin ligase degra-
dation and suppressing MUL1mitochondrial targeting, thus pre-
venting MUL1-mediated MFN2 ubiquitination and degradation.
This VPS35-MUL1-MFN2 pathway is in line with the reports
that MUL1/MAPL promotes ubiquitination and degradation of
MFN2 and enhances mitochondrial fission (Braschi et al., 2009;
Lokireddy et al., 2012). It is also in agreement with the observa-
tions that VPS35 interacts with MUL1/MAPL and is required for
the formation of MUL1/MAPL-associated mitochondrial-derived
vesicles (MDVs) or MUL1/MAPL-containing peroxisomes in the
MCF7 tumor cell line (Braschi et al., 2010). While this model isthors
supported by both in vitro and in vivo evidence, it is intriguing and
raises additional questions. How does VPS35 regulate MUL1/
MAPL degradation? Are the sorting nexins and other retromer
complex proteins (e.g., Vps26 and 29) involved in this event?
Does MUL1/MAPL-mediated Drp1 sumoylation also contribute
to the mitochondrial deficit in VPS35-deficient cells/brain? Ad-
dressing these questions in future studies may reveal further in-
sights into VPS35/retromer regulation of mitochondrial fusion/
fission dynamics and PD pathogenesis.
Notice that altered mitochondrial morphology or fusion dy-
namics were not only detected in VPS35-deficient DA neurons,
but also in VPS35-depleted neuroblastoma cell lines. These
results suggest that VPS35 may be a general regulator for mito-
chondrial fusion dynamics in vitro. However, in vivo/in VPS35+/
brain, dysfunctional mitochondria appeared to be brain region
selective and age dependent, mainly detected in PD-vulnerable
brain regions, such as SNpc and STR (Figure S4). Consistently,
the MUL1 increase and MFN2 reduction in VPS35-deficient
mice were also brain region selective, having been detected in
SNpc and STR, but not HIP (Figures 2 and 5). These observations
suggest a brain region-specific factor that also may regulate
MUL1 degradation and mitochondrial function. This factor may
be higher in the HIP, but lower in the SNpc and STR. Alterna-
tively, additional factor(s) that occur in VPS35-deficient midbrain
lower the threshold to tolerate VPS35/retromer dysfunction in DA
neurons as compared to that in other types of neurons, which
may contribute to the different results between in vitro and in vivo
experiments.
In aggregate, this study provides evidence that loss of VPS35
function in DA neurons results in impaired MUL1 trafficking
and degradation and increased MUL1, thus promoting MFN2
degradation, mitochondrial fusion and function impairments,
and dopaminergic neuronal loss.
EXPERIMENTAL PROCEDURES
Animals
Two types of VPS35-deficient mice were generated and used in this study.
First, VPS35+/ mice were described previously (Wen et al., 2011). Second,
VPS35DAT-Cre mice were generated by crossing floxed allele of VPS35
(VPS35f/f) with DAT-Cre mice. The VPS35f/f mice were generated as described
in the Supplemental Experimental Procedures. All the mice were backcrossed
with C57BL/6 mice for more than six to ten generations. All the mice were
housed in a room with a 12-hr light/dark cycle with water and standard rodent
chow diet. All the experimental procedures were approved by the Institutional
Animal Care and Use Committee at Georgia Regents University.
Stereological Analysis
To quantify the number of DA (TH+) or NeuN+ neurons in SNpc, the unbiased
stereological estimation of the total number of the TH+/NeuN+ cells in VM
was employed as previously described (Yin et al., 2013). In brief, every fifth
section from the bregma 2.92 to 4.16-mm coronal sections across the
midbrain was stained with TH/NeuN antibody. The total number of TH+/
NeuN+ neurons in each section of SNpc was mathematically calculated using
the Stereo Investigator program.
Primary Culture and Transfection
Dopaminergic neuronal culture was prepared as previously described (Lin
et al., 2012). Briefly, individual VM of embryonic day (E)18.5 VPS35f/f or
VPS35+/m mice was dissected and placed in cold Hank’s balanced salt solu-
tion (HBSS). The brain pieces were then digested in papain (5 U/ml, Worthing-Cell Reton Biochemical) for 20 min at 37C. Cells were dissociated using increasingly
smaller pipette tips, washed twice, resuspended in the plating medium (80%
Neurobasal-A and 20% fetal bovine serum), and plated onto poly-D-lysine-
coated coverslips at a density of 130,000 cells/well (24-well plate). The growth
media supplemented with 13 B27, 2 mM GlutaMAX-1, and 1% penicillin/
streptomycin were replaced 4 hr later. At 6 days in vitro (DIV), neurons were
subjected to transient transfection by using the calcium phosphate-mediated
gene transfer method, as previously described (Zhu et al., 2007).
OCR Measurement
OCR was analyzed in an X96 Extracellular Flux Analyzer with XF Cell Mito
Stress test kit (Seahorse Biosciences) at 37C. DA neurons were plated on
poly-D-lysine-coated XF96 cell culture plate at 40,000 per well and cultured
for 7 days with 80 ml neuronal culture medium/well. Four wells without neuron
seeding from each plate were set as temperature and background control.
For measurement, neurons were rinsed gently with 100 ml/well assay medium
(XF Base medium [Seahorse Biosciences] with 2 mM glutamine and 10 mM
glucose), put into 175 ml/well fresh assay medium, and assayed. Three
baseline recordings were made, followed by sequential injection of the ATP
synthase inhibitor oligomycin, the mitochondrial uncoupler FCCP, and the
complex I inhibitor rotenone. Two-minute OCR measurements were per-
formed at 3-min intervals with mixing, and each condition was measured in
an independent well.
Measurement of Mitochondrial Membrane Potential
Mitochondrial membrane potential (DJm) was measured with a cationic fluo-
rescent dye, TMRM+ (Molecular Probes). Briefly, NLT cells were transfected
with miR-scramble or miR-VPS35 on poly-D-lysine-coated coverslips, and,
48 hr post-transfection, cells were washed and incubated with TMRM+ at
10 nM for 30 min in a Dulbecco’s PBS (D-PBS, HyClone). After treatment, cells
were imaged at an excitation wavelength of 555 nm and emission wavelength
of 580 nm by the fluorescencemicroscope (Olympus IX70) and captured every
60 s with a 603 objective (Olympus); further analysis of TMRM fluorescence
was performed using Image-Pro Plus software.
AAV Generation and Injection
Adenovirus 5 carrying shRNA against mouse-MUL1 (AAV-shR-MUL1) was
generated at the Emory virus core facility. The shR-MUL1 (50- GAGCTGTGC
GGTCTGTTAA-30) was synthetized and subcloned into a pAAV-U6-GFP
expression vector (Cell Biolabs). The eGFP cDNA was used as a control after
sub-cloning into pAAV-MCS vector (Cell Biolabs). The full length of mouse
VPS35-D620N cDNA was sub-cloned into the pAAV-EGFP-T2A-V5 vector
(Vector Biolabs). Infected 293 cells from 25–50 15-cm tissue culture plates
were collected and centrifuged. Then the cells were lysed by three freeze/
thaw cycles. The AAV virus was purified using the iodixanol gradient centrifu-
gation procedure and the virus titers weremeasured by real-time PCR. For ste-
reotaxic injection, 1.5 ml viral solution (1 3 1012 vg/ml) was injected into the
right VM (anterior, 2.8 mm; lateral, 1.3 mm; dorsal, 4.2 mm relative to
bregma) with a 30-gauge microsyringe at a rate of 0.5 ml/min.
Statistical Analysis
Data were analyzed with Prism 5.0 software (GraphPad). Student’s t test and
one-way ANOVA with Bonferroni post hoc test were used as indicated. Signif-
icance was defined as p < 0.05.
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